Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2023 Filed Oct 5, 2023 23:56 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 6,566 | $8.61 | $56,512.25 |
DisclosureSEC source: 0000950170-23-052244 · ownership.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,066 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.52 to $8.66, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 23:56 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 13,500 | $8.27 | $111,662.55 |
DisclosureSEC source: 0000950170-23-052244 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.00 to $8.51, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:56 UTC |
Johnson David MichaelDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015206 · doc4.xml · derivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:57 UTC |
Mattessich Antony C.Director
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015209 · doc4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:56 UTC |
PAREKH RAJESH BDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015205 · doc4.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:54 UTC |
Srivastava SapnaDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015203 · doc4.xml · derivative · entry 1 Srivastava Sapna · CIK 0001569226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:35 UTC |
de los Pinos ElisabetDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 187,500 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002434 · doc4.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2033-01-18 F3 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:35 UTC |
de los Pinos ElisabetDirector · See Remarks
|
GrantCommon Stock | 121,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002434 · doc4.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,526 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:38 UTC |
Feder Julie BChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002437 · doc4.xml · derivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-18 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:38 UTC |
Feder Julie BChief Financial Officer
|
GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002437 · doc4.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,985 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:36 UTC |
De Rosch MarkChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002436 · doc4.xml · derivative · entry 2 De Rosch Mark · CIK 0001890320 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-01-18 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:36 UTC |
De Rosch MarkChief Operating Officer
|
GrantCommon Stock | 42,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002436 · doc4.xml · nonDerivative · entry 1 De Rosch Mark · CIK 0001890320 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,635 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:34 UTC |
Rich CadmusSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 52,500 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002433 · doc4.xml · derivative · entry 2 Rich Cadmus · CIK 0001890326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2033-01-18 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:34 UTC |
Rich CadmusSee Remarks
|
GrantCommon Stock | 34,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002433 · doc4.xml · nonDerivative · entry 1 Rich Cadmus · CIK 0001890326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,703 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:55 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 904 | $10.51 | $9,501.04 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 18,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:55 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 700 | $10.50 | $7,350.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 18,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:55 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 96 | $10.00 | $960.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 17,096 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:55 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 300 | $10.00 | $3,000.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 17,300 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:01 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 2,000 | $9.75 | $19,500.00 |
DisclosureSEC source: 0000899243-22-039594 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 17,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:01 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 2,000 | $9.75 | $19,500.00 |
DisclosureSEC source: 0000899243-22-039594 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 17,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:30 UTC |
GOEL DAVID E.10% owner
|
PurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | 1,250,000 | $12.00 | $15,000,000.00 |
DisclosureSEC source: 0000902664-22-005061 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,362,870 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 01, 2022 Filed Dec 15, 2022 23:15 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 5,000 | $12.37 | $61,850.00 |
DisclosureSEC source: 0000899243-22-038695 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 15,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 01, 2022 Filed Dec 15, 2022 23:15 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 5,000 | $12.37 | $61,850.00 |
DisclosureSEC source: 0000899243-22-038695 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 15,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:37 UTC |
de los Pinos ElisabetDirector · See Remarks
|
SaleCommon Stock | 5,706 | $12.46 | $71,081.92 |
DisclosureSEC source: 0000899243-22-034836 · doc4.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,651 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:39 UTC |
Feder Julie BChief Financial Officer
|
SaleCommon Stock | 2,015 | $12.45 | $25,089.57 |
DisclosureSEC source: 0000899243-22-034838 · doc4.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,235 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.487, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:38 UTC |
Rich CadmusSee Remarks
|
SaleCommon Stock | 1,672 | $12.45 | $20,813.22 |
DisclosureSEC source: 0000899243-22-034837 · doc4.xml · nonDerivative · entry 1 Rich Cadmus · CIK 0001890326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,578 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.40 to $12.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:36 UTC |
De Rosch MarkChief Operating Officer
|
SaleCommon Stock | 1,115 | $12.46 | $13,890.00 |
DisclosureSEC source: 0000899243-22-034834 · doc4.xml · nonDerivative · entry 1 De Rosch Mark · CIK 0001890320 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,385 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:07 UTC |
Johnson David MichaelDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023128 · doc4.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F4 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:06 UTC |
Mattessich Antony C.Director
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023125 · doc4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:09 UTC |
PAREKH RAJESH BDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023131 · doc4.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:07 UTC |
Srivastava SapnaDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023127 · doc4.xml · derivative · entry 1 Srivastava Sapna · CIK 0001569226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 20,000 | $13.99 | $279,800.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 6 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 7,000 | $13.99 | $97,930.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 10,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 7,000 | $13.99 | $97,930.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 10,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 10,000 | $15.04 | $150,400.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 3,000 | $15.04 | $45,120.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 3,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC |
Johnson David MichaelDirector
|
PurchaseCommon Stock | 3,000 | $15.04 | $45,120.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 3,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 20:11 UTC |
Johnson David MichaelDirector
|
ConversionSeries E Convertible Preferred Stock · Derivative | 139,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042361 · doc4.xml · derivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Velocity Capital Management LLC Disclosed balance after: 0 Underlying: Common Stock · 139,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: Velosity Capital Management LLC is an entity that the reporting person is the sole member of. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 20:11 UTC |
Johnson David MichaelDirector
|
ConversionCommon Stock | 139,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042361 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Velocity Capital Management Disclosed balance after: 139,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: Velosity Capital Management LLC is an entity that the reporting person is the sole member of. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC |
de los Pinos ElisabetDirector · See Remarks
|
ConversionSeries A-2 Preferred Stock · Derivative | 1,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 4 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 1,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC |
de los Pinos ElisabetDirector · See Remarks
|
ConversionSeries A-1 Preferred Stock · Derivative | 3,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 3,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC |
de los Pinos ElisabetDirector · See Remarks
|
ConversionCommon Stock | 4,552 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · nonDerivative · entry 2 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 131,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries E Convertible Preferred Stock · Derivative | 5,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 10 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries D-2 Convertible Preferred Stock · Derivative | 8,876 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 9 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries D-1 Convertible Preferred Stock · Derivative | 39,214 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 8 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 39,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries E Convertible Preferred Stock · Derivative | 251,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 7 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 251,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries D-2 Convertible Preferred Stock · Derivative | 373,606 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 6 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 373,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionSeries D-1 Convertible Preferred Stock · Derivative | 1,650,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · derivative · entry 5 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,650,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
PurchaseCommon Stock | 16,475 | $14.00 | $230,650.00 |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · nonDerivative · entry 4 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 70,540 F3 · ownership.nature: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:00 UTC |
Medicxi Growth I LP10% owner
Medicxi Growth Co-Invest I LP10% owner
Medicxi Growth I GP Ltd10% owner
|
ConversionCommon Stock | 54,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-043033 · doc4.xml · nonDerivative · entry 3 Medicxi Ventures Management (Jersey) Ltd · CIK 0001715579 · 10% owner Medicxi Growth I LP · CIK 0001690310 · 10% owner Medicxi Growth Co-Invest I LP · CIK 0001715578 · 10% owner Medicxi Growth I GP Ltd · CIK 0001715600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 54,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The number of shares of Common Stock contained in Column 4 of Table I, Rows 1 and 3, are the combined total of each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock which immediately prior to the closing of the Issuer's initial public offering ("IPO") converted into shares of the Issuer's Common Stock, on a 13.7-for one basis without payment or further consideration and had no expiration date. F1 · price: The number of shares of Common Stock contained in Column 4 of Table I, Rows 1 and 3, are the combined total of each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock which immediately prior to the closing of the Issuer's initial public offering ("IPO") converted into shares of the Issuer's Common Stock, on a 13.7-for one basis without payment or further consideration and had no expiration date. F3 · ownership.nature: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.